Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis

Lupus

Volumn 21, Issue 14, 2012, Pages 1492-1496

  Doria, A ^a   Gatto, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

anti C1q; anti dsDNA; lupus nephritis; nephritogenic autoantibodies; protective autoantibodies; Systemic lupus erythematosus

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C1Q ANTIBODY; DEOXYRIBONUCLEASE I; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 6; L SELECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEPHRITOGENIC ANTIBODY; NEPHRITOGENIC ANTIGEN; PENTRAXIN 3; UNCLASSIFIED DRUG;

APOPTOSIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHROMATIN; CYTOKINE RELEASE; ENZYME ACTIVITY; GLOMERULUS BASEMENT MEMBRANE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; APOPTOSIS; AUTOANTIBODIES; CHROMATIN; DNA; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; NUCLEOSOMES;

EID: 84869466655     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312462267     Document Type: Review

References (50)

1. Doria A, Zen M, Canova M, et al. SLE diagnosis and treatment: When early is early. Autoimmun Rev. 2010 ; 10: 55-60
2. Doria A, Iaccarino L, Ghirardello A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006 ; 119: 1497-1499
3. Clatworthy ML, Smith KG. B cells in glomerulonephritis: Focus on lupus nephritis. Semin Immunopathol. 2007 ; 29: 337-353
4. Kaalaji M, Fenton KA, Mortensen ES, et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int. 2007 ; 71: 664-672
5. Ghirardello A, Doria A, Zampieri S, et al. Antinucleosome antibodies in SLE: A two-year follow-up study of 101 patients. J Autoimmunity. 2004 ; 22: 235-240
6. Muñoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol. 2010 ; 6: 280-289
7. Kruse C, Janko C, Urbonaviciute V, et al. Inefficient clearance of dying cells in patients with SLE: Anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis. 2010 ; 15: 1098-1113
8. Fransen JH, van der Vlag J, Ruben J, Adema GJ, Berden JH, Hilbrands LB. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther. 2010 ; 12: 207-207
9. van Bavel CC, van der Vlag J, Berden JH. Glomerular binding of anti-dsDNA autoantibodies: The dispute resolved?. Kidney Int. 2007 ; 71: 600-601
10. van Bavel CC, Fenton KA, Rekvig OP, van der Vlag J, Berden JH. Glomerular targets of nephritogenic autoantibodies in systemic lupus erythematosus. Arthritis Rheum. 2008 ; 58: 1892-1899
11. Mjelle JE, Kalaaji M, Rekvig OP. Exposure of chromatin and not high affinity for dsDNA determines the nephritogenic impact of anti-dsDNA antibodies in (NZB×NZW)F1 mice. Autoimmunity. 2009 ; 42: 104-111
12. Rekvig OP, Putterman C, Casu C, et al. Autoantibodies in lupus: Culprits or passive bystanders?. Autoimmun Rev. 2012 ; 11: 596-603
13. Fenton K, Fismen S, Hedberg A. Anti-dsDNA antibodies promote initiation, and acquired loss of renal Dnase1 promotes progression of lupus nephritis in autoimmune (NZB×NZW)F1 mice. PLoS One. 2009 ; 4: e8474 - e8474
14. Zykova SN, Tveita AA, Rekvig OP. Renal Dnase1 enzyme activity and protein expression is selectively shut down in murine and human membranoproliferative lupus nephritis. PLoS One. 2010 ; 5 pii: e12096 - e12096
15. Fenton K, Tømmerås B, Marion TN, Rekvig OP. Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice. Autoimmunity. 2010 ; 43: 179-188
16. Villalta D, Romelli PB, Savina C, et al. Anti-dsDNA antibody avidity determination by a simple reliable ELISA method for SLE diagnosis and monitoring. Lupus. 2003 ; 12: 31-36
17. Krishnan MR, Wang C, Marion TN. Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice. Kidney Int. 2012 ; 82: 184-192
18. Witte T, Hartung K, Matthias T, et al. Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus. Rheumatol Int. 1998 ; 18: 63-69
19. Villalta D, Bizzaro N, Bassi N, et al. Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA anti-dsDNA helps to identify glomerulonephritis and active disease. 2012 (submitted).
20. Daha NA, Banda NK, Roos A, et al. Complement activation by (auto-) antibodies. Mol Immunol. 2011 ; 48: 1656-1665
21. Sato N, Ohsawa I, Nagamachi S, et al. Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus. 2011 ; 20: 1378-1386
22. Charles N, Hardwick D, Daugas E, Illei GG, Rivera J. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med. 2010 ; 16: 701-707
23. Davidson A, Diamond B. Activated basophils give lupus a booster shot. Nat Med. 2010 ; 16: 635-636
24. Hayashi T, Hasegawa K, Sasaki Y, Mori T, Adachi C, Maeda K. Systemic administration of interleukin-4 expressing plasmid DNA delays the development of glomerulonephritis and prolongs survival in lupus-prone female NZB × NZW F1 mice. Nephrol Dial Transplant. 2007 ; 22: 3131-3138
25. Pisetsky DS. Antinuclear antibodies in rheumatic disease: A proposal for a function-based classification. Scand J Immunol. 2012 ; 76: 223-228
26. Witte T, Hartung K, Sachse C, et al. IgM anti-dsDNA antibodies in systemic lupus erythematosus: Negative association with nephritis. Rheumatol Int. 1998 ; 18: 85-91
27. Förger F, Matthias T, Oppermann M, Becker H, Helmke K. Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus. 2004 ; 14: 36-44
28. Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A. 2000 ; 97: 1184-1189
29. Werwitzke S, Trick D, Kamino K, et al. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB × NZW) F1 mouse. Arthritis Rheum. 2005 ; 52: 3629-3638
30. Witte T. IgM antibodies against dsDNA in SLE. Clin Rev Allerg Immunol. 2008 ; 34: 345-347
31. Shoenfeld Y, Toubi E. Protective autoantibodies. Role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum. 2005 ; 52: 2599-2606
32. Zen M, Bassi N, Nalotto L, et al. Disease activity patterns in a monocentric cohort of SLE patients: A seven-year follow-up study. Clin Exp Rheumatol. Epub ahead of print 5 July 2012. PubMed PMID: 22765883.
33. Ghirardello A, Villalta D, Morozzi G, et al. Diagnostic accuracy of currently available anti-double stranded DNA antibody assay. An Italian multicenter study. Clin Exp Rheumatol. 2011 ; 29: 50-56
34. Shoenfeld Y, Szyper-Kravitz M, Witte T, et al. Autoantibodies against protective molecules - C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: Prevalence in systemic lupus erythematosus. Ann N Y Acad Sci. 2007 ; 1108: 227-239
35. Pickering MC, Botto M. Are anti-C1q antibodies different from other SLE autoantibodies?. Nat Rev Rheumatol. 2010 ; 6: 490-493
36. Katsumata Y, Miyake K, Kawaguchi Y. Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: A controlled study of 126 consecutive patients. Arthritis Rheum. 2011 ; 63: 2436-2444
37. Bigler C, Hopfer H, Danner D, Schaller M, Mihatsch MJ, Trendelenburg M. Anti-C1q autoantibodies do not correlate with the occurrence or severity of experimental lupus nephritis. Nephrol Dial Transplant. 2011 ; 26: 1220-1228
38. Schaller M, Bigler C, Danner D, Ditzel HJ, Trendelenburg M. Autoantibodies against C1q in systemic lupus erythematosus are antigen-driven. J Immunol. 2009 ; 183: 8225-8231
39. Gasque P. Complement: A unique innate immune sensor for danger signals. Mol Immunol. 2004 ; 41: 1089-1098
40. Gaipl US, Beyer TD, Heyder P. Cooperation between C1q and DNase I in the clearance of necrotic cell-derived chromatin. Arthritis Rheum. 2004 ; 50: 640-649
41. Rhodes B, Vyse TJ. The genetics of SLE: An update in the light of genome-wide association studies. Rheumatology. 2008 ; 47: 1603-1611
42. Zandman-Goddard G, Blank M, Langevitz P, et al. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity. Ann Rheum Dis. 2005 ; 64: 1698-1702
43. Figueredo MA, Rodriguez A, Ruiz-Yagüe M, et al. Autoantibodies against C-reactive protein: Clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol. 2006 ; 33: 1980-1986
44. Janko C, Franz S, Munoz LE, et al. CRP/anti-CRP antibodies assembly on the surfaces of cell remnants switches their phagocytic clearance toward inflammation. Front Immunol. 2011 ; 2: 70-70
45. Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol. 2008 ; 20: 538-544
46. Bassi N, Zampieri S, Ghirardello A, et al. Pentraxins, anti-pentraxin antibodies, and atherosclerosis. Clin Rev Allergy Immunol. 2009 ; 37: 36-43
47. Jaillon S, Peri G, Delneste Y, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med. 2007 ; 204: 793-804
48. Nauta AJ, Bottazzi B, Mantovani A, Salvatori G, Kishore U, Schwaeble WJ. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol. 2003 ; 33: 465-473
49. Rovere P, Peri G, Fazzini F, et al. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood. 2000 ; 96: 4300-4306
50. Bassi N, Ghirardello A, Blank M, et al. IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis. 2010 ; 69: 1704-1710